MedTrace Logo

Endoscopic Retrograde Cholangiopancreatography

NCT07490132 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2026-03-24

No results posted yet for this study

Summary

The risk of post-endoscopic retrograde cholangiopancreatography(ERCP) pancreatitis(PEP) is influenced by patient and procedure-related factors. Strategies to decrease PEP(Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis) are of great importance.

Conditions

  • Gastro-Intestinal Disorder

Interventions

OTHER

Patients undergoing ERCPs at Methodist Dallas Medical Center

The registry will include all patients who meet registry inclusion. Enrollment will terminate once 25 years of data are captured: January 1, 2000 through December 31, 2025.

Sponsors & Collaborators

  • Methodist Health System

    lead OTHER

Principal Investigators

  • Prashant Kedia, MD · Methodist Health System

Eligibility

Min Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-28
Primary Completion
2027-02-28
Completion
2028-02-29

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07490132 on ClinicalTrials.gov